IS5713A - Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini - Google Patents

Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini

Info

Publication number
IS5713A
IS5713A IS5713A IS5713A IS5713A IS 5713 A IS5713 A IS 5713A IS 5713 A IS5713 A IS 5713A IS 5713 A IS5713 A IS 5713A IS 5713 A IS5713 A IS 5713A
Authority
IS
Iceland
Prior art keywords
cancer
protein
mixtures
treatment
hmg coa
Prior art date
Application number
IS5713A
Other languages
English (en)
Inventor
Leopold Judith
Schofield-Newton Roger
Original Assignee
Warner - Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner - Lambert Company, , Delaware Corporation filed Critical Warner - Lambert Company, , Delaware Corporation
Publication of IS5713A publication Critical patent/IS5713A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS5713A 1998-05-12 2000-11-10 Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini IS5713A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8520298P 1998-05-12 1998-05-12
US9225398P 1998-07-10 1998-07-10
PCT/US1999/010188 WO1999058505A2 (en) 1998-05-12 1999-05-10 Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer

Publications (1)

Publication Number Publication Date
IS5713A true IS5713A (is) 2000-11-10

Family

ID=26772425

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5713A IS5713A (is) 1998-05-12 2000-11-10 Blöndur prótín-farnesýlfærsluensíms- og HMG COA afoxunarensímstálma og notkun þeirra til meðhöndlunar á krabbameini

Country Status (25)

Country Link
US (1) US6492410B1 (is)
EP (1) EP1077949A2 (is)
JP (1) JP2002514628A (is)
KR (1) KR20010043529A (is)
CN (1) CN1171874C (is)
AP (1) AP2000001984A0 (is)
AU (1) AU758891B2 (is)
BG (1) BG105003A (is)
BR (1) BR9911785A (is)
CA (1) CA2331295A1 (is)
EA (1) EA003860B1 (is)
EE (1) EE200000660A (is)
GE (1) GEP20032996B (is)
HR (1) HRP20000771A2 (is)
HU (1) HUP0102322A3 (is)
ID (1) ID27933A (is)
IL (1) IL139502A0 (is)
IS (1) IS5713A (is)
NO (1) NO20005680L (is)
NZ (1) NZ508357A (is)
OA (1) OA11551A (is)
PL (1) PL344662A1 (is)
SK (1) SK16742000A3 (is)
WO (1) WO1999058505A2 (is)
YU (1) YU68900A (is)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363088A1 (en) * 1999-02-11 2000-08-17 Patrick T. Prendergast Methods for treating viral infections
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
US20020010128A1 (en) * 2000-04-13 2002-01-24 Parks Thomas P. Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism
US20020132781A1 (en) * 2000-10-06 2002-09-19 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
WO2005042710A1 (en) * 2003-10-28 2005-05-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of statin to kill ebv-transformed b cells
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
KR100930365B1 (ko) * 2006-11-09 2009-12-08 덕성여자대학교 산학협력단 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물
US20080119444A1 (en) * 2006-11-16 2008-05-22 Steven Lehrer Methods and compositions for the treatment of cancer
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK523288A (da) * 1987-10-06 1989-04-07 Hoffmann La Roche Aminosyrederivater
NL9002031A (nl) 1990-09-14 1992-04-01 Voskuilen Woudenberg Bv Inrichting voor het bewerken van een uitwendig buisoppervlak.
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
KR19990028303A (ko) * 1995-06-22 1999-04-15 한센 핀 베네드, 안네 제헤르 성장호르몬 방출 특성을 가지는 화합물
JPH11508262A (ja) 1995-06-22 1999-07-21 バイオジェン，インコーポレイテッド Ｃｄ４０リガンドのフラグメントの結晶およびその使用
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування

Also Published As

Publication number Publication date
EA003860B1 (ru) 2003-10-30
NO20005680D0 (no) 2000-11-10
HRP20000771A2 (en) 2001-06-30
CN1171874C (zh) 2004-10-20
NO20005680L (no) 2001-01-10
AU3979299A (en) 1999-11-29
YU68900A (sh) 2002-12-10
IL139502A0 (en) 2001-11-25
OA11551A (en) 2004-05-24
PL344662A1 (en) 2001-11-19
WO1999058505A3 (en) 2000-01-06
SK16742000A3 (sk) 2001-07-10
JP2002514628A (ja) 2002-05-21
WO1999058505A2 (en) 1999-11-18
BG105003A (en) 2001-07-31
AU758891B2 (en) 2003-04-03
BR9911785A (pt) 2001-04-03
EA200001164A1 (ru) 2001-06-25
HUP0102322A2 (hu) 2001-11-28
US6492410B1 (en) 2002-12-10
ID27933A (id) 2001-05-03
GEP20032996B (en) 2003-06-25
EP1077949A2 (en) 2001-02-28
HUP0102322A3 (en) 2001-12-28
EE200000660A (et) 2002-04-15
NZ508357A (en) 2002-09-27
CN1306515A (zh) 2001-08-01
CA2331295A1 (en) 1999-11-18
AP2000001984A0 (en) 2000-12-31
KR20010043529A (ko) 2001-05-25
HK1038355A1 (en) 2002-03-15

Similar Documents

Publication Publication Date Title
NO990296D0 (no) HPPD-genet og inhibitorer
NO983576L (no) Br°nnbehandlingsfluider og fremgangsmÕter
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK1105123T3 (da) Farmaceutiske præparater indeholdende lipase-inhibitorer og chitosan
NO20022656D0 (no) Caspaseinhibitorer og anvendelse derav
NO20005190L (no) Terapeutiske angiogene faktorer og fremgangsmåter til anvendelse derav
NO20000996L (no) Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel
NO991150D0 (no) Pyrazolopyrimidiner og pyrazolotriaziner
NO20012689D0 (no) Nye fluider og teknikker for matriks syrebehandling
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO991700D0 (no) Benzimidazol-2-karbamater for behandling av virusinfeksjoner og cancer
NO991701D0 (no) HIV og cancer behandling
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
NO980218D0 (no) p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling
NO20002189L (no) Anvendelse av makrolider for behandling av cancer og mukuladegenerasjon
NO20005680L (no) Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer
IS5246A (is) Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum
ID23014A (id) INHIBITOR FARNESIL TRANSFERASE DALAM KOMBINASI DENGAN INHIBITOR HMG CoA REDUKTASE UNTUK PENGOBATAN KANKER
NO954321D0 (no) 4-aryl-4-hydroksy-tetrahydropyraner og 3-aryl-3-hydroksy-tetrahydrofuraner som 5-lipoksygenase-inhibitorer
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
NO20006626D0 (no) Beleggingsmiddel og anvendelse herav
AU2002340251A8 (en) Use of mx gtpases in the prognosis and treatment of cancer